Eylea meets 52-week endpoint in Phase III for diabetic retinopathy subset

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said both dosing schedules of Eylea aflibercept met the 52-week primary endpoint in the Phase III PANORAMA trial for early intervention of non-proliferative diabetic retinopathy without diabetic macular edema (DME). The company reported in March that Eylea met

Read the full 421 word article

User Sign In